본문으로 건너뛰기
← 뒤로

Investigating the Causal Effect of Potential Therapeutic Agents for Colorectal Cancer Prevention: A Mendelian Randomization Analysis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2026 Vol.35(1) p. 95-108

Fryer E, Bishop DT, Campbell PT, Chan AT, Le Marchand L, Li CI, Moreno V, Gunter MJ, Phipps AI, Grant RC, Schmit SL, Martin RM, Yarmolinsky J, Haycock P

📝 환자 설명용 한 줄

[BACKGROUND] Conventional observational studies have identified several potential therapeutic agents that may lower the risk of colorectal cancer development.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • OR 1.10

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Fryer E, Bishop DT, et al. (2026). Investigating the Causal Effect of Potential Therapeutic Agents for Colorectal Cancer Prevention: A Mendelian Randomization Analysis.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 35(1), 95-108. https://doi.org/10.1158/1055-9965.EPI-25-0875
MLA Fryer E, et al.. "Investigating the Causal Effect of Potential Therapeutic Agents for Colorectal Cancer Prevention: A Mendelian Randomization Analysis.." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol. 35, no. 1, 2026, pp. 95-108.
PMID 41085561

Abstract

[BACKGROUND] Conventional observational studies have identified several potential therapeutic agents that may lower the risk of colorectal cancer development. However, these studies are susceptible to unmeasured and residual confounding and reverse causation, undermining robust causal inference.

[METHODS] We used Mendelian randomization, a genetic epidemiologic method that can strengthen causal inference, to evaluate the effect of previously reported therapeutic agents on colorectal cancer risk, including medications, dietary micronutrients, and exogenous hormones. Genetic instruments were constructed using genome-wide association studies (GWAS) of molecular traits (e.g., circulating levels of protein drug targets, blood-based biomarkers of micronutrients, and circulating levels of endogenous hormones). Using summary statistics from these GWASs and a colorectal cancer risk GWAS (cases = 78,473; controls = 107,143), we employed Wald ratios and inverse-variance weighted models to estimate causal effects.

[RESULTS] We found evidence for associations of genetically proxied elevated omega-3 fatty acids (OR = 1.10; 95% confidence interval, 1.03-1.18; P = 6.20 × 10-3) and reduced plasma angiotensin-converting enzyme (ACE) levels (OR = 1.08; 95% confidence interval, 1.03-1.13; P = 9.36 × 10-4) with colorectal cancer risk. Findings for ACE inhibition were consistent across sensitivity analyses.

[CONCLUSIONS] Reduced plasma ACE levels were robustly linked to increased colorectal cancer risk. Further work is required to better understand the mechanism behind this finding and whether this translates to adverse effects via medication use (i.e., ACE inhibitors).

[IMPACT] These findings provide updated evidence on the role of previously reported therapeutic agents in colorectal cancer risk, helping prioritize further evaluation of those agents with potential etiologic roles in cancer development.

MeSH Terms

Mendelian Randomization Analysis; Colorectal Neoplasms; Genome-Wide Association Study; Fatty Acids, Omega-3; Odds Ratio; Peptidyl-Dipeptidase A; Angiotensin-Converting Enzyme Inhibitors; Risk Factors; Biomarkers; Micronutrients; Humans; Male; Female; Antineoplastic Agents